Stereotactic body radiation therapy and thymosin alpha-1-induced anti-tumor effects in heavily pretreated, metastatic esophageal squamous cell carcinoma patients

Oncoimmunology
Dexi DuShixiu Wu

Abstract

This study investigated the anti-tumor effects of stereotactic body radiation therapy (SBRT) with thymosin alpha-1 (Tα1) in heavily pretreated, metastatic esophageal squamous cell carcinoma (mESCC) patients. Thirty-one patients with at least 2 metastatic sites were enrolled. SBRT was delivered with a daily fraction of 5.0 Gy for a total dosage of 25 Gy over one week to one metastatic lesion. Concurrent Tα1 (1.6mg subcutaneously) was administered twice a week with an interval of 3-4 days until tumor progression of other documented metastatic lesions. Anti-tumor effects (the primary endpoint) were evaluated by assessing the CT/MRI response of other distinct measurable lesions. Secondary endpoints included treatment safety, survival outcomes and immune-related blood parameters. This study was registered at ClinicalTrials.gov (NCT 02545751). Partial response occurred in three (9.7%) patients, and 11 (35.5%) patients had stable metastatic disease, which yielded a metastatic-lesion control rate of 45.2%. Seventeen (54.8%) patients were documented to have progressive disease in other metastatic lesions. The median overall survival and abscopal progression free survival (APFS) times were 5.2 and 2.9 months, respectively. Significant di...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Jul 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·A L GoldsteinA White
Jan 4, 2001·International Journal of Immunopharmacology·E GaraciC Favalli
Aug 27, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·M Zahidunnabi DewanSandra Demaria
Jan 3, 2012·International Journal of Radiation Oncology, Biology, Physics·Dörthe SchaueWilliam H McBride
Oct 11, 2012·Annals of the New York Academy of Sciences·Enrico GaraciPaola Sinibaldi-Vallebona
Feb 25, 2014·Cancer Immunology Research·Encouse B GoldenSilvia C Formenti
Sep 5, 2014·Cancer Immunology Research·Chad TangJames W Welsh
Mar 25, 2015·Cancer Letters·Saumil J GandhiAmit Maity
Jan 26, 2016·CA: a Cancer Journal for Clinicians·Wanqing ChenJie He
May 21, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Antonin LevyEric Deutsch
Oct 16, 2016·Cancer Immunology, Immunotherapy : CII·Dan IshiharaRaquibul Hannan
Mar 6, 2017·Critical Reviews in Oncology/hematology·Enrique ChajonRenaud De Crevoisier
Apr 28, 2017·Frontiers in Oncology·Wilfred Ngwa, Zi Ouyang
May 26, 2017·The British Journal of Radiology·Evert J Van LimbergenPhilippe Lambin
Jun 27, 2017·Lancet·Jesper LagergrenPernilla Lagergren
Jul 28, 2017·Nature Reviews. Disease Primers·Elizabeth C SmythDavid Cunningham

❮ Previous
Next ❯

Citations

Jul 17, 2020·Frontiers in Pharmacology·Zhang-Ren ChenJin-Hua Wen

❮ Previous
Next ❯

Datasets Mentioned

BETA
GM-CSF

Methods Mentioned

BETA
flow cytometry

Clinical Trials Mentioned

NCT02545751

Software Mentioned

SPSS

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.